MicroRNA-92b-3p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinoma.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 03 10 2019
revised: 27 12 2019
accepted: 06 01 2020
pubmed: 25 1 2020
medline: 23 4 2020
entrez: 25 1 2020
Statut: ppublish

Résumé

Although several studies have reported that microRNA (miR)-92b-3p is involved in various cellular processes related to carcinogenesis, its physiological role in clear cell renal cell carcinoma (ccRCC) remains unclear. To clarify the role of miR-92b-3p in ccRCC, we compared miR-92b-3p expression levels in ccRCC tissues and adjacent normal renal tissues. Significant upregulation of miR-92b-3p was observed in ccRCC tissues. Overexpression of miR-92b-3p using a miRNA mimic promoted proliferation, migration, and invasion activities of ACHN cells. Functional inhibition of miR-92b-3p by a hairpin miRNA inhibitor suppressed Caki-2 cell growth and invasion activities in vitro. Mechanistically, it was found that miR-92b-3p directly targeted the TSC1 gene, a known upstream regulator of mTOR. Overexpression of miR-92b-3p decreased the protein expression of TSC1 and enhanced the downstream phosphorylation of p70S6 kinase, suggesting that the mTOR signaling pathway was activated by miR-92b-3p in RCC cells. Importantly, a multivariate Cox proportion hazard model, based on TNM staging and high levels of miR-92b-3p, revealed that miR-92b-3p expression (high vs. low hazard ratio, 2.86; 95% confidence interval, 1.20-6.83; P = .018) was a significant prognostic factor for overall survival of ccRCC patients with surgical management. Taken together, miR-92b-3p was found to act as an oncomiR, promoting cell proliferation by downregulating TSC1 in ccRCC.

Identifiants

pubmed: 31975504
doi: 10.1111/cas.14325
pmc: PMC7156823
doi:

Substances chimiques

Biomarkers, Tumor 0
MIRN92 microRNA, human 0
MicroRNAs 0
TSC1 protein, human 0
Tuberous Sclerosis Complex 1 Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1146-1155

Subventions

Organisme : Japan Society for the Promotion of Science
ID : Grant number: A16H069540

Informations de copyright

© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
pubmed: 19143635
Brain Res. 2013 Sep 5;1529:16-25
pubmed: 23892108
Mol Cancer. 2017 Oct 27;16(1):167
pubmed: 29078789
Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52
pubmed: 25378301
Cell Rep. 2018 Jul 31;24(5):1093-1104.e6
pubmed: 30067967
Oncol Rep. 2014 Feb;31(2):613-8
pubmed: 24317477
Mol Oncol. 2012 Dec;6(6):590-610
pubmed: 23102669
Oncol Lett. 2018 Apr;15(4):6003-6008
pubmed: 29552228
Cancer Sci. 2020 Apr;111(4):1146-1155
pubmed: 31975504
Biochem Biophys Res Commun. 2013 Nov 1;440(4):604-10
pubmed: 24099768
Oncol Rep. 2015 Apr;33(4):1571-8
pubmed: 25682771
Bioinformatics. 2014 Jun 1;30(11):1630-2
pubmed: 24519378
Cell Mol Life Sci. 2017 Jul;74(14):2613-2625
pubmed: 28238105
Oncotarget. 2015 Aug 28;6(25):21645-54
pubmed: 26046464
DNA Cell Biol. 2018 May;37(5):501-511
pubmed: 29638162
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
Mol Cancer Res. 2015 Mar;13(3):565-74
pubmed: 25381221
Int J Oncol. 2017 Jul;51(1):289-297
pubmed: 28534944
Onco Targets Ther. 2014 Feb 27;7:365-74
pubmed: 24600236
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Int J Oncol. 2016 Dec;49(6):2589-2599
pubmed: 27779660
Mol Cancer Res. 2011 Sep;9(9):1255-65
pubmed: 21798997
Int J Urol. 2007 Jun;14(6):479-82
pubmed: 17593088
Biometrika. 1965 Jun;52:203-23
pubmed: 14341275

Auteurs

Cong Wang (C)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Motohide Uemura (M)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Urological Immuno-Oncology, Osaka University Graduate School of Medicine, Suita, Japan.

Eisuke Tomiyama (E)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Makoto Matsushita (M)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Yoko Koh (Y)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Kosuke Nakano (K)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Yujiro Hayashi (Y)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Yu Ishizuya (Y)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Kentaro Jingushi (K)

Laboratory of Molecular and Cellular Physiology, Osaka University Graduate School of Pharmaceutical Sciences, Suita, Japan.

Taigo Kato (T)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Urological Immuno-Oncology, Osaka University Graduate School of Medicine, Suita, Japan.

Koji Hatano (K)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Atsunari Kawashima (A)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Takeshi Ujike (T)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Akira Nagahara (A)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Kazutoshi Fujita (K)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Ryoichi Imamura (R)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Kazutake Tsujikawa (K)

Laboratory of Molecular and Cellular Physiology, Osaka University Graduate School of Pharmaceutical Sciences, Suita, Japan.

Norio Nonomura (N)

Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH